Cyberattacks against accounting software firm Wolters Kluwer and the City of Baltimore in May showed how the newest wave of malicious hacking can have significant, often...Technologyread more
The European parliamentary election is the second largest democratic exercise in the world.Europe Newsread more
Biden had criticized Kim Jong Un as a "dictator" and a "tyrant" at a recent rally in Philadelphia. North Korean state media responded by calling Biden a "fool of low IQ" among...Politicsread more
Buybacks have gotten a bad rap from both Republicans and Democrats. But stocks would be trading at a massive discount without them.Marketsread more
Fiat Chrysler and France's Renault could soon partner up to take on the sweeping changes to the global auto industry, according to a report in the Financial Times. The...Autosread more
Microsoft shares have gained 133% since November 2015, outperforming a tech "basket of unicorns" over that stretch.Technologyread more
The president's state visit comes amid tensions with carmaker Toyota over potential auto tariffs. Trump has repeatedly threatened Japanese and European carmakers with tariffs.Traderead more
The IRS is about to release a new draft of Form W-4, which will more closely reflect the changes stemming from the Tax Cuts and Jobs Act. For workers, that means they'll need...Personal Financeread more
The Mega Millions jackpot has spilled over $400 million. It would be the ninth largest winning since the game began in 2002.Personal Financeread more
Trump was speaking at a meeting of Japanese business leaders in Tokyo during his state visit to Japan on Saturday.Marketsread more
The biggest U.S. gasoline price surge in years is running out of steam just in time for the start of the summer driving season.Energyread more
April 30 (Reuters) - Amgen Inc on Tuesday reported first-quarter revenue that was unchanged from a year ago and net income fell 14 percent as sales of key drugs, including new migraine treatment Aimovig and cholesterol fighter Repatha, face competition and pressure to lower prices.
But the world's largest biotechnology company still raised the lower end of its full-year earnings and sales forecasts as adjusted profit topped expectations.
Excluding items, Amgen's adjusted earnings were $3.56 per share. Wall Street analysts, on average, expected $3.47, according to IBES data from Refinitiv.
Net income fell 14 percent to $2 billion as costs for manufacturing as well as research and development increased.
Revenue for the quarter of $5.56 billion showed no growth but was in line with analyst estimates.
Aimovig sales totaled $59 million for the quarter, short of the $83.3 million projected by analysts and down from $95 million in the fourth quarter.
Sales of Repatha at $141 million also came in below Wall Street estimates of $158.7 million.
Higher unit demand for Repatha was "offset substantially" by lower net prices, Amgen said. The company recently launched a lower-priced Repatha option aimed at reducing out-of-pocket costs for Medicare patients.
Aimovig competes with similar new migraine drugs from Eli Lilly and Co and Teva Pharmaceuticals Industries Ltd for placement on pharmacy benefit plans, which typically demand discounts or rebates from the list price in exchange for coverage.
Faced with new competition, first-quarter sales of Amgen's kidney drug Sensipar fell 57 percent to $213 million, below the $353.4 million forecast by analysts.
For the full year, Amgen said it now expects adjusted earnings per share of $13.25 to $14.30 on revenue of $22 billion to $22.9 billion, compared with previous forecasts of $13.10 to $14.30 per share and revenue of $21.8 billion to $22.9 billion. (Reporting By Deena Beasley Editing by Bill Berkrot)